JP2017523207A - ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用 - Google Patents

ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用 Download PDF

Info

Publication number
JP2017523207A
JP2017523207A JP2017505609A JP2017505609A JP2017523207A JP 2017523207 A JP2017523207 A JP 2017523207A JP 2017505609 A JP2017505609 A JP 2017505609A JP 2017505609 A JP2017505609 A JP 2017505609A JP 2017523207 A JP2017523207 A JP 2017523207A
Authority
JP
Japan
Prior art keywords
inhibitor
cell
mcl
anticancer agent
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017505609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523207A5 (enExample
Inventor
クオ，ス−ピン
シエ，シン−カン
チャン，ベティー
シュエ，リン
チュン，レオ
バラスブラマニアン，スリラム
Original Assignee
ファーマサイクリックス エルエルシー
ファーマサイクリックス エルエルシー
ジャンセン ファーマシューティカ エヌブイ
ジャンセン ファーマシューティカ エヌブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマサイクリックス エルエルシー, ファーマサイクリックス エルエルシー, ジャンセン ファーマシューティカ エヌブイ, ジャンセン ファーマシューティカ エヌブイ filed Critical ファーマサイクリックス エルエルシー
Publication of JP2017523207A publication Critical patent/JP2017523207A/ja
Publication of JP2017523207A5 publication Critical patent/JP2017523207A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017505609A 2014-08-08 2015-08-06 ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用 Pending JP2017523207A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462034997P 2014-08-08 2014-08-08
US62/034,997 2014-08-08
US201462082972P 2014-11-21 2014-11-21
US62/082,972 2014-11-21
US201462086162P 2014-12-01 2014-12-01
US62/086,162 2014-12-01
US201562196251P 2015-07-23 2015-07-23
US62/196,251 2015-07-23
PCT/US2015/044095 WO2016022853A1 (en) 2014-08-08 2015-08-06 Bruton's tyrosine kinase inhibitor combinations and uses thereof

Publications (2)

Publication Number Publication Date
JP2017523207A true JP2017523207A (ja) 2017-08-17
JP2017523207A5 JP2017523207A5 (enExample) 2018-09-13

Family

ID=55264587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505609A Pending JP2017523207A (ja) 2014-08-08 2015-08-06 ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用

Country Status (10)

Country Link
US (2) US9730938B2 (enExample)
EP (1) EP3177366A4 (enExample)
JP (1) JP2017523207A (enExample)
CN (1) CN106714909A (enExample)
AU (1) AU2015300966A1 (enExample)
BR (1) BR112017002232A2 (enExample)
CA (1) CA2956550A1 (enExample)
MX (1) MX2017001656A (enExample)
TW (1) TWI586354B (enExample)
WO (1) WO2016022853A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516974A (ja) * 2019-01-09 2022-03-03 セルジーン コーポレイション 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法
JP2023539729A (ja) * 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤の非晶質形態及びその製剤

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
WO2016071770A2 (en) * 2014-11-05 2016-05-12 Janssen Pharmaceutica Nv Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
MX2018014577A (es) 2016-05-27 2019-05-20 Tg Therapeutics Inc Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
KR20190141695A (ko) 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
WO2019070777A2 (en) * 2017-10-04 2019-04-11 University Of Maryland, Baltimore County PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS FOR THE TREATMENT OF CANCERS
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
BR112021016400A2 (pt) 2019-02-22 2021-10-13 Janssen Pharmaceutica N.V. Forma cristalina de mono-hidrato de 1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil.)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
EP3871665B1 (en) 2020-02-28 2025-12-24 Martin-Luther-Universität Halle-Wittenberg Inhibitors of rna-binding proteins as anti-cancer drugs
US20240139205A1 (en) * 2020-03-05 2024-05-02 Universite De Lausanne Modulators of aralar for treating neurological disorders
JP2023533014A (ja) * 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
EP3967307A1 (en) * 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions
CN114469949A (zh) * 2020-10-27 2022-05-13 正大天晴药业集团股份有限公司 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物
EP4301365A1 (en) * 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
TW202515550A (zh) * 2023-06-29 2025-04-16 大陸商上海翰森生物醫藥科技有限公司 三并環類抑制劑與抗癌劑在製備抗腫瘤藥物中的聯合應用
WO2025262118A1 (en) * 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7832117B2 (en) * 2006-07-17 2010-11-16 Nike, Inc. Article of footwear including full length composite plate
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
US20150182490A1 (en) * 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ＢＬＯＯＤ, vol. 123, no. 6, JPN6019020222, February 2014 (2014-02-01), pages 905 - 913, ISSN: 0004182304 *
ＢＲＩＴＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ, vol. 107, no. 3, JPN6019020220, 2012, pages 491 - 500, ISSN: 0004182303 *
ＢＲＩＴＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＨＡＥＭＡＴＯＬＯＧＹ, vol. 161, no. 1, JPN6019020210, 2013, pages 43 - 56, ISSN: 0004182296 *
ＣＡＮＣＥＲ ＣＥＬＬ, vol. 22, no. 6, JPN6019020201, 2012, pages 812 - 824, ISSN: 0004182291 *
ＣＡＮＣＥＲ ＣＥＬＬ, vol. 22, no. 6, JPN6019020206, 2012, pages 706 - 707, ISSN: 0004182294 *
ＣＨＥＭＩＣＡＬ ＡＮＤ ＢＩＯＬＯＧＹ, vol. 19, no. 9, JPN6019020213, 2012, pages 1082 - 1083, ISSN: 0004182298 *
ＣＨＥＭＩＣＡＬ ＡＮＤ ＢＩＯＬＯＧＹ, vol. 19, no. 9, JPN6019020214, 2012, pages 1175 - 1186, ISSN: 0004182299 *
ＣＬＩＮＩＣＡＬ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, vol. 19, no. 24, JPN6019020202, 2013, pages 6662 - 6668, ISSN: 0004182292 *
ＭＯＬＥＣＵＬＡＲ ＣＡＮＣＥＲ ＴＨＥＲＡＰＥＵＴＩＣＳ, vol. 11, no. 5, JPN6019020211, 2012, pages 1122 - 1132, ISSN: 0004182297 *
ＯＮＣＯＴＡＲＧＥＴ, vol. 3, no. 12, JPN6019020204, 2012, pages 1489 - 1490, ISSN: 0004182293 *
ＰＲＯＣ．ＮＡＴＬ．ＡＣＡＤ．ＳＣＩ．ＵＳＡ, vol. 108, no. 1, JPN6019020219, 2011, pages 272 - 277, ISSN: 0004182302 *
ＰＲＯＣ．ＮＡＴＬ．ＡＣＡＤ．ＳＣＩ．ＵＳＡ, vol. 110, no. 4, JPN6019020217, 2013, pages 1398 - 1403, ISSN: 0004182301 *
ＰＲＯＣ．ＮＡＴＬ．ＡＣＡＤ．ＳＣＩ．ＵＳＡ, vol. 111, no. 6, JPN6019020208, February 2014 (2014-02-01), pages 2349 - 2354, ISSN: 0004182295 *
ＳＣＩＥＮＣＥ, vol. 340, JPN6019020216, 2013, pages 626 - 630, ISSN: 0004182300 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516974A (ja) * 2019-01-09 2022-03-03 セルジーン コーポレイション 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法
JP7467479B2 (ja) 2019-01-09 2024-04-15 セルジーン コーポレイション 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法
JP2023539729A (ja) * 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤の非晶質形態及びその製剤

Also Published As

Publication number Publication date
TW201609107A (zh) 2016-03-16
US9730938B2 (en) 2017-08-15
TWI586354B (zh) 2017-06-11
US20160038495A1 (en) 2016-02-11
WO2016022853A1 (en) 2016-02-11
EP3177366A4 (en) 2018-04-04
CA2956550A1 (en) 2016-02-11
AU2015300966A1 (en) 2017-02-16
BR112017002232A2 (pt) 2018-07-24
CN106714909A (zh) 2017-05-24
MX2017001656A (es) 2017-07-24
US20180071295A1 (en) 2018-03-15
EP3177366A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
US11318138B2 (en) Methods for treating B cell proliferative disorders
US9730938B2 (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof
US20220249494A1 (en) Use of inhibitors of brutons tyrosine kinase (btk)
KR102054468B1 (ko) 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US20160032404A1 (en) Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
US20220106317A1 (en) Solvated forms of a bruton's tyrosine kinase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191225